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Table 1. Procedural outcome (n¼194)
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Device success 188 (96.9) 91 (93.8) 97 (100.0) 0.03
post procedural
permanent
pacemaker
implantation
12 (6.6) 10 (10.3 2 (2.1) 0.02
New left bundle
branch block
40 /165 25 /76 15 /89 0.02
Paravalvular AR
 2
39 (20.1) 25 (25.8) 14 (14.4) 0.05
30-day mortality 12 (6.2) 10 (10.3) 2 (2.2) <0.01
Values are n (%) or mean  SD.
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Background: Transcatheter aortic valve implantation (TAVI) bears the risk of severe
intraprocedural complications that may require emergent cardiac surgery (ECS).
However, few data exist on the incidence, reasons and outcomes of those needing
ECS.
Methods: We analyzed data from 2307 TAVI patients, prospectively enrolled in the
multicenter Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE)
registry.
Results: Twenty-seven (1.2%) of 2307 patients required ECS. Rates of ECS were
similar for patients undergoing TA-TAVI as compared to those undergoing TF-TAVI
(1.1% vs. 1.2%, p¼n.s.). The leading causes for ECS were embolization/migration of
the TAVI valve prosthesis (9/27, 33%) and procedure-related aortic injury (n¼7,
26%). Outcomes were grave with early mortality of 51.9% within 30 days, showing
some differences in survival with different causes of ECS.
Conclusions: Rates of ECS during TAVI were low, with embolization/dislocation of
the prosthesis and aortic injury being the most common causes. Although ECS was
performed without time delay, outcomes were associated with grave prognosis with
half of the patients dying within 30 days. Prevention of complications requiring ECS
during TAVI thus appears of critical importance. Reﬁnements in TAVI should be
directed towards development of less traumatic, more ﬂexible delivery catheter
systems and retrievable valves to reduce the risk of aortic injury and valve
embolization.
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Background: Currently, both the self-expandable Medtronic CoreValve (MCV)
(Medtronic Inc., Minneapolis, Minnesota) and the balloon-expandable Edwards
SAPIEN/SAPIEN XT (ES) prostheses (Edwards Lifesciences, Irvine, California), are
widely used in transcatheter aortic valve implantation (TAVI). The aim of this study
was to compare procedural outcome and 30-day mortality after transfemoral TAVI
with the MCV versus the ES prosthesis.
Methods: At out center, the transfemoral TAVI program was started late 2007 with
the MCV prosthesis exclusively; late 2010 we started implanting both the MCV and
the ES prosthesis at the operator's discretion. All patients (n¼194) who underwent
a transfemoral TAVI between June 2010 and June 2013 with either the self-
expandable MCV (n¼97) or the ES prosthesis (n¼97) were included. We performed
a prosthesis-based comparison to evaluate differences in procedural outcome and 30-
day mortality.
Results: Mean age was 80.37.2 years, 35% were male. Device success according to
the Valve Academic Research Consortium criteria in the MCV group was 94%
compared to 100% in the ES group (p¼ 0.03). Postprocedural complications were
more frequently encountered in patients treated with the MCV compared to the
patients treated with the ES prosthesis (table 1). Type of prosthesis was an indepen-
dent predictor of 30-day mortality after multivariate adjustment for identiﬁed baseline
characteristics (HR 0.087).JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Postprocedural complication rate as well as short-term mortality after
a transfemoral TAVI with a Medtronic CoreValve prosthesis was higher compared to
the Edwards SAPIEN/SAPIEN XT prosthesis. Prosthesis type was associated with
cardiac mortality after multivariate adjustment for identiﬁed baseline predictors
(hazard ratio, 0.087; 95% conﬁdence interval, 0.10–0.72; p¼0.02)
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Background: Both general anaesthesia as well as sedation plus local analgesia are
options for the periprocedural anaesthetic management of transfemoral transcatheter
aortic valve implantation (TAVI); We report a single center experience on the safety,
feasibility, procedural characteristics and 30-day outcomes of transfemoral TAVI
using exclusively local anesthesia and ﬂuoroscopic guidance.
Methods: Consecutive patients planned for transfemoral TAVI with at discretion of
the operator, either the Medtronic CoreValve (Medtronic Inc., Minneapolis, Min-
nesota)(n¼78) or the Edwards Sapien/SapienXT (Edwards Lifesciences, Irvine, Cal-
ifornia)(n¼102) prosthesis, between October 2010 and June 2013 were included in
this study. Periprocedural anaesthetic management, procedural characteristics and
early outcomes were assessed.
Results: 180 patients were included (34% male). 178 were planned under local
analgesia, of which 4 were converted to general anaesthesia (2.2%). Reasons for
conversion were conversion to surgery due to prosthesis embolization in one patient;
in 2 patients, the puncture or closure of peripheral vasculature was reason for
conversion; one procedure was converted because of restlessness of the patient. In
none of the cases periprocedural transesophageal echocardiography was necessary.
The mean procedure duration was 9739 minutes. Premedication one hour prior to
the procedure included temazepam, lorazepam or midazolam in 75.5% of patients. No
premedication was administered in 24.5% of patients. Device success was 96.7%.
Mean Aortic Valve area increased from 0.79 to 2.2 cm2. 9 patients developed
a delirium during the admission (5%). At 30 days, all-cause mortality was 9 (5%) and
NYHA Class decreased from preprocedural 3 0.6 to 1 0.9.
Conclusions: Transfemoral TAVI performed using exclusively local analgesia and
ﬂuoroscopic guidance is safe and feasible with a very low rate of conversion. This
anaesthetic management may be beneﬁcial in the fragile TAVI-patient population.acts/POSTER/Aortic Valve Disease and Treatment B219
